Fig. 3

BsAb-armed T cells enhanced the cancer-killing capacity. T cells cultured with anti-PSMA/anti-CD3 BsAbs (called BsAb-armed T cell) or OKT3 (called OKT3-T cell) were applied at different ratios (effector cell/target cell ratios of 3:1, 5:1, or 10:1) and added to A LNCaP or PC-3 for 18 h. The anti-cancer efficiency of each group was detected by using the CytoTox 96 Non-Radioactive Cytotoxicity Assay. B, C The cytotoxins (perforin and granzyme B) and cytokines (IL-2, INF-γ, and TNF-α) released from T cell co-cultured with LNCaP or PC-3 cells were analyzed by commercial ELISA kits. D The ex vivo T cell targeting and killing efficiency to LNCaP were observed by real-time and live-cell imaging system. E The tumor cell area were be qualified by ImageJ and compared with control in each timepoint. Bar, SD; **p < 0.01; ***p < 0.001